<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320521">
  <stage>Registered</stage>
  <submitdate>25/03/2010</submitdate>
  <approvaldate>6/10/2010</approvaldate>
  <actrnumber>ACTRN12610000835044</actrnumber>
  <trial_identification>
    <studytitle>Influence on hemodynamics of conversion from Calcineurin Inhibitor to Sirolimus in Renal and Liver Transplant patients</studytitle>
    <scientifictitle>Influence on hemodynamics of conversion from Calcineurin Inhibitor to Sirolimus in Renal and Liver Transplant patients older than 18 year</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Cochrane Renal Group, CRG110600099</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>renal allograft recipients or liver allograft recipients</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Switch calcineurin inhibitor (CNI) to Sirolimus treatment;
Sirolimus dose:Loading dose 10-15 mg/d (at clinicians discretion); d 2-6:3-5 mg/d (at clinicians discretion), after d 7,sirolimus dosage was adjusted to target through level of 616 ng/mL 
study duration: 1 year. 
administration: oral capsule</interventions>
    <comparator>remain on CNI, dose in relation to CNI-Through levels of 80-180 ng/ml, duration: 1 year, mode of administration: oral capsule
difference between control and intervention group: type of immunosuppressive regime for liver transplant patients ( either CNI treatment or Sirolimus treatment)
at study inclusion, all patients have been on CNI treatment for at least 6 months after liver transplantation</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>-renal resistance index assessed by dopplersonography</outcome>
      <timepoint>one year following randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>-aortic stiffness measured by pulse plethysmography


-</outcome>
      <timepoint>one year following randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>-renal function test: analysis of plasma creatinine levels</outcome>
      <timepoint>one year following randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>patient and graft survival
tools: data linkage to medical records</outcome>
      <timepoint>one year following randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>-incidence of treated acute rejections
tools: data linkage to medical records</outcome>
      <timepoint>one year following randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>-arterial hypertension
test: automatic sphygmomanometer</outcome>
      <timepoint>one year following randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>-incidence of hyperlipidemia/ diabetes mellitus
-severity of hyperlipidemia/ diabete mellitus
test: blood analysis of cholesterol and glycosilated hemiglobin</outcome>
      <timepoint>one year following randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-renal of liver allograft recipient
-creatinine clearance &gt; 30ml/min</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- signs of acute rejection

- evidence of active systemic or localised major infection

-known or suspected malignancy ( exception skin malignancies)

- -renal arterial stenosis &gt; 50 % reduction in luminal diameter

-hydronephros</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/09/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>University Hospital Bern</primarysponsorname>
    <primarysponsoraddress>Department of Nephrology
Freiburgstr. 10
3010 Bern</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication>Eisenberger U, Sollinger D, Stickel F, Burckhardt B, Frey FJ. 
Relationship between Renal Resistance Index and Renal Function in Liver Transplant Recipients after Cessation of Calcineurin Inhibitor.
Clinical Transplantation 2009, 23(4): 499-504</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>PD Dr. Ute, Eisenberger, ,</name>
      <address>Senior Resident, Nephrology, University Hospital Bern, Freiburgstr. 10</address>
      <phone>+41 31 6323144</phone>
      <fax />
      <email>ute.eisenberger@insel.ch</email>
      <country>Switzerland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>PD Dr. Ute, Eisenberger</name>
      <address>Senior Resident, Nephrology, University Hospital Bern, Freiburgstr. 10</address>
      <phone>+41 31 6323144</phone>
      <fax />
      <email>ute.eisenberger@insel.ch</email>
      <country>Switzerland</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>